2019

Pillar Biosciences, an NGS diagnostics company based in Boston, MA, announced today that Pillar® ONCO/Reveal™ NGS panels are now compatible with Illumina®, Ion Torrent™, and MGI™ sequencing platforms. Additionally, Pillar has entered into a co-marketing agreement with MGI that will highlight the compatibility between Pillar’s NGS assays and MGI’s sequencing platform-agnostic sample prep robotics. “With …

Pillar NGS panels go global with increased platform versatility Read More »

BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, a next-generation sequencing (NGS) panel, received conditional approval by the New York State Department of Health for clinical use by the Laboratory of Personalized Genomic Medicine at Columbia University Medical …

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel Read More »

SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming a strategic partnership and joint venture with China Biotech Services Holdings, Ltd (CBSH; HKSE:08037). The agreement was signed on January 9th at the JP Morgan Healthcare Conference in San Francisco. …

Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia Read More »